
Shinichiro Takahashi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4707234/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival. Clinical Cancer Research, 2012, 18, 3686-3696.	3.2	246
2	Glypicanâ€3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Science, 2009, 100, 1403-1407.	1.7	222
3	Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05) Journal of Clinical Oncology, 2019, 37, 189-189.	0.8	185
4	Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. OncoImmunology, 2016, 5, e1129483.	2.1	125
5	Evaluation of the Prognostic Factors and Significance of Lymph Node Status in Invasive Ductal Carcinoma of the Body or Tail of the Pancreas. Pancreas, 2010, 39, e48-e54.	0.5	62
6	Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes. International Journal of Oncology, 2012, 40, 63-70.	1.4	54
7	Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer. Annals of Surgery, 2022, 276, e510-e517.	2.1	33
8	Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems. Scientific Reports, 2020, 10, 18278.	1.6	29
9	Clinicopathological features of stomach cancer with invasive micropapillary component. Gastric Cancer, 2012, 15, 179-187.	2.7	24
10	Relationship Between the Histological Type of Initial Lesions and the Risk for the Development of Remnant Gastric Cancers After Gastrectomy for Synchronous Multiple Gastric Cancers. World Journal of Surgery, 2010, 34, 296-302.	0.8	20
11	Peptide vaccine as an adjuvant therapy for glypicanâ€3â€positive hepatocellular carcinoma induces peptideâ€specific CTLs and improves long prognosis. Cancer Science, 2020, 111, 2747-2759.	1.7	19
12	Area of residual tumor (ART) can predict prognosis after post neoadjuvant therapy resection for pancreatic ductal adenocarcinoma. Scientific Reports, 2019, 9, 17145.	1.6	15
13	Plasma and tumoral glypicanâ€3 levels are correlated in patients with hepatitis C virusâ€related hepatocellular carcinoma. Cancer Science, 2020, 111, 334-342.	1.7	13
14	Clinical and histopathological features of remnant gastric cancers, after gastrectomy for synchronous multiple gastric cancers. Journal of Surgical Oncology, 2009, 100, 466-471.	0.8	12
15	Adenocarcinoma of the minor duodenal papilla with intraepithelial spread to the pancreatic duct. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 451, 1075-1081.	1.4	11
16	Usefulness of plasma full‑length glypican‑3 as a predictive marker of hepatocellular carcinoma recurrence after radial surgery. Oncology Letters, 2020, 19, 2657-2666.	0.8	9
17	Measure of pancreas transection and postoperative pancreatic fistula. Journal of Surgical Research, 2016, 202, 276-283.	0.8	6
18	Relationship between surgical RO resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy in patients with borderline resectable pancreatic cancer. BMC Cancer, 2020, 20, 1184.	1.1	3